(Colorectal Cancer) Panitumumab + mFOLFOXIRI Effective?

On June 6, 2022, Daniele Rossini et al. from the University of Pisa published in the medical journal Journal of Clinical Oncology the efficacy and safety results of panitumumab plus mFOLFOXIRI as first-line treatment for patients with RAS/BRAF wild-type metastatic colorectal cancer in the TRIPLETE Phase III clinical trial.

The TRIPLETE Phase III trial randomized patients with RAS/BRAF wild-type metastatic colorectal cancer (N=435) in a 1:1 ratio into the panitumumab + mFOLFOXIRI group (N=218) and the panitumumab + mFOLFOX group (N=217). After 12 cycles, both groups continued with fluorouracil + leucovorin + panitumumab. The primary endpoint was objective response rate (ORR).

The primary endpoint ORR odds ratio was 0.87.

Other results: Early tumor shrinkage rate — panitumumab + mFOLFOXIRI 58% / panitumumab + mFOLFOX 57%; maximum tumor shrinkage rate — panitumumab + mFOLFOXIRI 47% / panitumumab + mFOLFOX 48%; R0 resection rate — panitumumab + mFOLFOXIRI 29% / panitumumab + mFOLFOX 25%; median PFS — panitumumab + mFOLFOXIRI 12.7 months / panitumumab + mFOLFOX 12.3 months.

Based on the TRIPLETE trial results, Daniele Rossini et al. concluded: In patients with RAS/BRAF wild-type metastatic colorectal cancer, panitumumab plus mFOLFOXIRI as first-line treatment showed no significant clinical benefit over panitumumab plus mFOLFOX.

Source: https://ascopubs.org/doi/full/10.1200/JCO.22.00839

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4

Related Cancer Information

• Colorectal cancer